Candidates for larynx preservation: the next step?

Area of Science:

• Oncology
• Head and Neck Cancer Research
• Laryngeal Cancer Treatment

Background:

• Larynx preservation is a key goal in head and neck cancer treatment, reducing the need for laryngectomy.
• Concurrent chemoradiotherapy has shown superior larynx preservation rates compared to older induction chemotherapy regimens.
• Concurrent chemoradiotherapy is associated with higher toxicity than induction chemotherapy followed by radiotherapy.

Purpose of the Study:

• To evaluate the effectiveness of different nonsurgical treatment strategies for larynx preservation.
• To compare concurrent chemoradiotherapy with induction chemotherapy regimens, including TPF (docetaxel, cisplatin, 5-FU).
• To explore novel treatment combinations, such as adding cetuximab to chemoradiotherapy.

Main Methods:

• Review of randomized trials comparing different chemotherapy and radiotherapy regimens.
• Analysis of induction chemotherapy regimens, specifically PF (cisplatin, 5-FU) and TPF.
• Investigation of concurrent chemoradiotherapy and radiotherapy plus cetuximab.

Main Results:

• Concurrent chemoradiotherapy is more effective for larynx preservation than PF-based induction chemotherapy.
• TPF induction chemotherapy is more effective than PF and is a standard for future trials.
• Concurrent chemoradiotherapy has higher toxicity than induction chemotherapy followed by radiotherapy.

Conclusions:

• Concurrent chemoradiotherapy is a promising approach for larynx preservation but requires careful toxicity management.
• Further research, including international collaborative trials, is necessary to optimize treatment strategies.
• Comparing concurrent chemoradiotherapy with sequential TPF induction followed by radiotherapy or cetuximab plus radiotherapy is crucial for determining the best approach for larynx preservation, disease control, and survival.